Mucopolysaccharidosis II

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

Registry of Patients Diagnosed With Lysosomal Storage Diseases

Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type II

MPS (RaDiCo Cohort) (RaDiCo-MPS)

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects

ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program

UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells

Baby Detect : Genomic Newborn Screening

A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II

A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21)

An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II

A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ

MPS II Immunophenotyping

A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II